Literature DB >> 19423538

Common genetic variation in TP53 and risk of human papillomavirus persistence and progression to CIN3/cancer revisited.

Jill Koshiol1, Allan Hildesheim, Paula Gonzalez, M Concepcion Bratti, Carolina Porras, Mark Schiffman, Rolando Herrero, Ana C Rodriguez, Sholom Wacholder, Meredith Yeager, Stephen J Chanock, Robert D Burk, Sophia S Wang.   

Abstract

Driven by findings that human papillomavirus (HPV)-induced degradation of p53 differs by a TP53 polymorphism at codon 72 (Pro72Arg), past studies of TP53 genetic variants and cervical cancer have focused on this nonsynonymous polymorphism, with mixed results. We analyzed common single nucleotide polymorphisms (SNP) across the TP53 locus in a population-based nested case-control study in Guanacaste, Costa Rica. We evaluated 11 SNPs, including Pro72Arg (rs1042522), among 1,281 women: 465 with cervical intraepithelial neoplasia grade 3/cancer (CIN3+), 380 with HPV persistence (median, 25 months), and 436 random population controls. We combined HPV persistence and CIN3+ into one case group because they did not differ in TP53 genotypic frequencies and calculated odds ratios and 95% confidence intervals (CI) for individual SNPs and inferred haplotypes. We observed that proline at codon 72 was associated with increased risk of CIN3+/persistence compared with population controls. Relative to GG (Arg), the CG (Pro/Arg) and CC (Pro) genotypes had a 1.3-fold (95% CI, 0.99-1.6) and 1.8-fold (95% CI, 1.2-2.7) increased risk, respectively (P(trend) < 0.01). rs12951053 and rs1642785 were also associated with CIN3+/persistence (P (trend), 0.05 and 0.04, respectively), as was a haplotype containing the codon 72 variant (rs1042522), rs12951053, rs1642785, and rs12947788 (odds ratio, 1.6; 95% CI, 1.1-2.3 versus the most common haplotype, which comprised the major alleles for all 11 SNPs). Although genetic variation in TP53 might affect the natural history of HPV and cervical cancer, further work is needed to elucidate the possible mechanism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19423538      PMCID: PMC2764239          DOI: 10.1158/1055-9965.EPI-08-0830

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  31 in total

1.  Assessing the probability that a positive report is false: an approach for molecular epidemiology studies.

Authors:  Sholom Wacholder; Stephen Chanock; Montserrat Garcia-Closas; Laure El Ghormli; Nathaniel Rothman
Journal:  J Natl Cancer Inst       Date:  2004-03-17       Impact factor: 13.506

2.  Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project.

Authors:  R Herrero; M H Schiffman; C Bratti; A Hildesheim; I Balmaceda; M E Sherman; M Greenberg; F Cárdenas; V Gómez; K Helgesen; J Morales; M Hutchinson; L Mango; M Alfaro; N W Potischman; S Wacholder; C Swanson; L A Brinton
Journal:  Rev Panam Salud Publica       Date:  1997-05

3.  p53 polymorphisms and haplotypes in different ethnic groups.

Authors:  A Själander; R Birgander; A Kivelä; G Beckman
Journal:  Hum Hered       Date:  1995 May-Jun       Impact factor: 0.444

4.  Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population.

Authors:  L Excoffier; M Slatkin
Journal:  Mol Biol Evol       Date:  1995-09       Impact factor: 16.240

Review 5.  Natural history of cervical intraepithelial neoplasia: a critical review.

Authors:  A G Ostör
Journal:  Int J Gynecol Pathol       Date:  1993-04       Impact factor: 2.762

6.  High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation.

Authors:  X Li; P Coffino
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis.

Authors:  S H Jee; S Y Won; J E Yun; J E Lee; J S Park; S S Ji
Journal:  Int J Gynaecol Obstet       Date:  2004-06       Impact factor: 3.561

8.  p53 at codon 72 polymorphism, human papillomavirus infection and cervical lesions: a cross-sectional study from northeastern Italy.

Authors:  Manola Comar; Gianna Dal Molin; Secondo Guaschino; Cesare Campello
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2004-06-15       Impact factor: 2.435

9.  Is p53 polymorphism maintained by natural selection?

Authors:  G Beckman; R Birgander; A Själander; N Saha; P A Holmberg; A Kivelä; L Beckman
Journal:  Hum Hered       Date:  1994 Sep-Oct       Impact factor: 0.444

Review 10.  p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review.

Authors:  Anita Koushik; Robert W Platt; Eduardo L Franco
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2004-01       Impact factor: 4.254

View more
  11 in total

1.  Cervix smear abnormalities: linking pathology data in female twins, their mothers and sisters.

Authors:  Jacqueline M Vink; Folkert J van Kemenade; Chris J L M Meijer; Mariel K Casparie; Gerrit A Meijer; Dorret I Boomsma
Journal:  Eur J Hum Genet       Date:  2010-08-18       Impact factor: 4.246

Review 2.  Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Authors:  Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó
Journal:  Pharmacogenomics       Date:  2016-09-16       Impact factor: 2.533

3.  A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia.

Authors:  Mark Schiffman; Ana Cecilia Rodriguez; Zigui Chen; Sholom Wacholder; Rolando Herrero; Allan Hildesheim; Rob Desalle; Brian Befano; Kai Yu; Mahboobeh Safaeian; Mark E Sherman; Jorge Morales; Diego Guillen; Mario Alfaro; Martha Hutchinson; Diane Solomon; Philip E Castle; Robert D Burk
Journal:  Cancer Res       Date:  2010-03-30       Impact factor: 12.701

4.  Association of TP53 codon 72 and intron 3 16-bp Ins/Del polymorphisms with cervical cancer risk.

Authors:  Tatiana Dantas Rodrigues Laprano; Erika Hardy Lemos; Lia Moreira Pinto Cunha; José Eleutério Júnior; Rosiane Alves de SousaTeles; Silvia Helena Barem Rabenhorst
Journal:  Tumour Biol       Date:  2014-04-30

Review 5.  Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis.

Authors:  Mohammad Haroon Khan; Aftab Khalil; Hamid Rashid
Journal:  Genet Res (Camb)       Date:  2015-04-17       Impact factor: 1.588

Review 6.  Clinical outcomes and correlates of TP53 mutations and cancer.

Authors:  Ana I Robles; Curtis C Harris
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-03       Impact factor: 10.005

7.  TP53 PIN3 and PEX4 polymorphisms and infertility associated with endometriosis or with post-in vitro fertilization implantation failure.

Authors:  D D Paskulin; J S L Cunha-Filho; C A B Souza; M C Bortolini; P Hainaut; P Ashton-Prolla
Journal:  Cell Death Dis       Date:  2012-09-27       Impact factor: 8.469

8.  Nucleotide Excision Repair Gene ERCC2 and ERCC5 Variants Increase Risk of Uterine Cervical Cancer.

Authors:  Jungnam Joo; Kyong-Ah Yoon; Tomonori Hayashi; Sun-Young Kong; Hye-Jin Shin; Boram Park; Young Min Kim; Sang-Hyun Hwang; Jeongseon Kim; Aesun Shin; Joo-Young Kim
Journal:  Cancer Res Treat       Date:  2015-06-22       Impact factor: 4.679

9.  Bonafide, type-specific human papillomavirus persistence among HIV-positive pregnant women: predictive value for cytological abnormalities, a longitudinal cohort study.

Authors:  Angela Ri Meyrelles; Juliana D Siqueira; Pâmela P Dos Santos; Cristina B Hofer; Ronir R Luiz; Héctor N Seuánez; Gutemberg Almeida; Marcelo A Soares; Esmeralda A Soares; Elizabeth S Machado
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-02       Impact factor: 2.743

10.  Polymorphism Located in the Upstream Region of the RPS19 Gene (rs2305809) Is Associated With Cervical Cancer: A Case-control Study.

Authors:  Thaís da Rocha Boeira; Janaina Coser; Jonas Michel Wolf; Bruna Klahr Manggini Cardinal; Ivana Grivicich; Daniel Simon; Vagner Ricardo Lunge
Journal:  J Cancer Prev       Date:  2018-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.